Key Laboratory of Protein and Peptide Pharmaceuticals and Laboratory of Proteomics, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.02200-19.
Polymyxins are increasingly used as the critical last-resort therapeutic options for multidrug-resistant Gram-negative bacteria. Unfortunately, polymyxin resistance has increased gradually over the past few years. Although studies on polymyxin mechanisms are expanding, systemwide analyses of the underlying mechanism for polymyxin resistance and stress response are still lacking. To understand how adapts to colistin (polymyxin E) pressure, we carried out proteomic analysis of a strain cultured with different concentrations of colistin. Our results showed that the proteomic responses to colistin treatment in involve several pathways, including (i) gluconeogenesis and the tricarboxylic acid (TCA) cycle, (ii) arginine biosynthesis, (iii) porphyrin and chlorophyll metabolism, and (iv) enterobactin biosynthesis. Interestingly, decreased abundances of class A β-lactamases, including TEM, SHV-11, and SHV-4, were observed in cells treated with colistin. Moreover, we present comprehensive proteome atlases of paired polymyxin-susceptible and -resistant strains. The polymyxin-resistant strain Ci, a mutant of ATCC BAA 2146, showed a missense mutation in This mutant, which displayed lipid A modification with 4-amino-4-deoxy-l-arabinose (l-Ara4N) and palmitoylation, showed striking increases in the expression of CrrAB, PmrAB, PhoPQ, ArnBCADT, and PagP. We hypothesize that mutations induce elevated expression of the operon and via PmrAB and PhoPQ. Moreover, the multidrug efflux pump KexD, which was induced by mutation, also contributed to colistin resistance. Overall, our results demonstrated proteomic responses to colistin treatment and the mechanism of CrrB-mediated colistin resistance, which may offer valuable information on the management of polymyxin resistance.
多黏菌素类药物被越来越多地用作治疗多重耐药革兰氏阴性菌的关键最后手段。不幸的是,多黏菌素耐药性在过去几年中逐渐增加。尽管多黏菌素机制的研究正在不断扩展,但对于多黏菌素耐药性和应激反应的潜在机制的系统分析仍然缺乏。为了了解 如何适应黏菌素(多黏菌素 E)的压力,我们对用不同浓度黏菌素培养的 菌株进行了蛋白质组学分析。我们的结果表明, 对黏菌素处理的蛋白质组学反应涉及几个途径,包括(i)糖异生和三羧酸(TCA)循环,(ii)精氨酸生物合成,(iii)卟啉和叶绿素代谢,和(iv)肠杆菌素生物合成。有趣的是,在用黏菌素处理的细胞中观察到 A 类β-内酰胺酶(包括 TEM、SHV-11 和 SHV-4)的丰度降低。此外,我们展示了配对的多黏菌素敏感和耐药 菌株的综合蛋白质组图谱。多黏菌素耐药菌株 Ci 是 ATCC BAA 2146 的突变体,在 中显示出一个错义突变。这个突变体显示出脂质 A 修饰带有 4-氨基-4-脱氧-l-阿拉伯糖(l-Ara4N)和棕榈酰化,导致 CrrAB、PmrAB、PhoPQ、ArnBCADT 和 PagP 的表达显著增加。我们假设 突变诱导了 操纵子和 通过 PmrAB 和 PhoPQ 的表达升高。此外,由 突变诱导的多药外排泵 KexD 也有助于黏菌素耐药性。总的来说,我们的结果展示了黏菌素处理的蛋白质组学反应和 CrrB 介导的黏菌素耐药性的机制,这可能为多黏菌素耐药性的管理提供有价值的信息。